These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19882073)

  • 1. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
    Hildemann SK; Bode C
    Hamostaseologie; 2009 Nov; 29(4):349-55. PubMed ID: 19882073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action and clinical development of platelet thrombin receptor antagonists.
    Ueno M; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1191-200. PubMed ID: 20670195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
    Oestreich J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):988-96. PubMed ID: 19705342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCH 530348: a novel oral thrombin receptor antagonist.
    Bonaca MP; Morrow DA
    Future Cardiol; 2009 Sep; 5(5):435-42. PubMed ID: 19715408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
    Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E;
    Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    White HD
    Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
    Macaulay TE; Allen C; Ziada KM
    Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease-activated receptor-1 antagonists: focus on SCH 530348.
    Sugunaraj JP; Mehta V; Kalra A; Sukhija R; Palaniswamy C
    Am J Ther; 2012 Nov; 19(6):465-9. PubMed ID: 21248619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
    TRA*CER Executive and Steering Committees
    Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
    Tomasello SD; Angiolillo DJ; Goto S
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.
    Chintala M; Shimizu K; Ogawa M; Yamaguchi H; Doi M; Jensen P
    J Pharmacol Sci; 2008 Dec; 108(4):433-8. PubMed ID: 19098390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
    Becker RC; Moliterno DJ; Jennings LK; Pieper KS; Pei J; Niederman A; Ziada KM; Berman G; Strony J; Joseph D; Mahaffey KW; Van de Werf F; Veltri E; Harrington RA;
    Lancet; 2009 Mar; 373(9667):919-28. PubMed ID: 19286091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical overview of promising nonthienopyridine antiplatelet agents.
    Angiolillo DJ; Guzman LA
    Am Heart J; 2008 Aug; 156(2 Suppl):S23-8. PubMed ID: 18657683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.
    Shinohara Y; Goto S; Doi M; Jensen P
    J Stroke Cerebrovasc Dis; 2012 May; 21(4):318-24. PubMed ID: 20947374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
    Duerschmied D; Bode C
    Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
    Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
    Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
    Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.